IMBiologics (Ticker: 493280 KS) is a South Korean company specializing in the research and development of innovative antibody drugs for autoimmune diseases and immuno-oncology. IMBiologics plans to list on the KOSDAQ on March 20, 2026, planning to offer 2,000,000 shares at a price of 26,000 KRW, raising 52.0 billion KRW ($35.09 million USD). Based on the total post-IPO shares, the company has an estimated market valuation of approximately 384.5 billion KRW ($259.49 million USD).

The underwriters for the offering are Korea Investment & Securities and Shinhan Investment & Securities. According to sources, the IPO saw strong demand, achieving an institutional competition ratio of 839.23 to 1. Additional facts indicate that the company operates a full-cycle drug development system and has previously secured significant technology transfer agreements for its lead pipeline assets, IMB-101 and IMB-102. Reportedly, the offering consists entirely of primary shares, with a 75 percent allocation to institutional investors and 25 percent to the general public.